Many incurable diseases (e.g., cancer, neurodegeneration) involve biomolecules called ‘disordered proteins’. Considered ‘undruggable’ by the mainstream pharmaceutical industry, disordered proteins continuously change their three-dimensional shapes and lack long-lived sites with which drug-molecules can interact. Our mission is to make disordered proteins druggable. We will screen millions of disordered protein/drug-molecule pairs to learn the rules of drugging disordered proteins. Building on our expertise and working with academic and industrial partners, we will leverage cutting-edge biology, engineering, and AI to deliver new drugs and tools. To accomplish this in a manner for maximum societal benefit, we have established a Focused Research Organisation (FRO), a fully-independent not-for-profit entity dedicated to this goal.
Company Details
- Employees
- 10
- Founded
- -
- Address
- Central London, Gb
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.bindresearch.org
- HQ
- Central London
Bind Research Questions
Bind Research's website is http://www.bindresearch.org
Bind Research's LinkedIn profile is https://uk.linkedin.com/company/bind-research
Bind Research has
10 employees.
View email and phone details for 10
employees at Bind Research.
Bind Research's industry is
Biotechnology Research
Bind Research's top competitors are
Isomorphic Labs,
Department For Science, Innovation And Technology,
Shellworks,
Deep Science Ventures,
Pharos Ai,
Convergent Research,
Pharosai,
Refeyn,
Infinitopes,
Latent Labs.
Bind Research's categories are Biotechnology Research
Bind Research's founding year is 2024
